However, it: Only results in modest weight loss (~5-7% body weight) Can cause gastrointestinal distress (diarrhea, nausea) Works best for those with insulin resistance rather than general obesity How GLP-1 and GIP Medications Offer Superior Weight Loss GLP-1 (Glucagon-Like Peptide-1) and GIP (Gastric Inhibitory Polypeptide) receptor agonists represent a new era in obesity treatment , working through multiple mechanisms to promote substantial and sustainable weight loss : Enhanced Appetite Suppression and Fullness GLP-1/GIP medications mimic natural gut hormones that regulate hunger and satiety, leading to: Significantly reduced appetite and cravings Longer-lasting fullness after meals No stimulant effects or addiction potential More Effective Weight Loss Compared to older medications, GLP-1 and GIP drugs produce greater and sustained weight loss : Tirzepatide (Mounjaro/Zepbound): 20-25% total body weight loss Semaglutide (Ozempic/Wegovy): 15-20% total body weight loss Phentermine & Topamax (Qsymia): 5-10% weight loss Metformin: 5-7% weight loss Long-Term Safety and Cardiometabolic Benefits Unlike Phentermine, which is only approved for short-term use , GLP-1/GIP medications are safe for long-term weight management
FormBlends pricing is available at checkout after provider consultation
It takes about two minutes per injection
Tip 2: Rotate injection sites and relax your muscles to reduce soreness and tissue irritation
Accordingly, detailed statistical comparisons between these two groups are emphasized only for outcomes showing differential responses. Clinical symptoms During the experiment, rats in the STZ-intoxicated group exhibited symptoms including increased body weight, polyphagia, polyuria, and polydipsia
